United Therapeutics Corp (STU:UTH)
€ 251 -5 (-1.95%) Market Cap: 11.20 Bil Enterprise Value: 9.25 Bil PE Ratio: 12.90 PB Ratio: 2.26 GF Score: 87/100

United Therapeutics Corp at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 16, 2021 / 07:10PM GMT
Release Date Price: €138 (+2.99%)
Hartaj Singh
Oppenheimer & Co. Inc., Research Division - Research Analyst

Great. Thank you, Kevin, so very much for dialing us in. And we have United Therapeutics, Dr. Martine Rothblatt; and then James Edgemond, also joining us. Whatever I say these names, I have to tell you all that I just get a little scared, I'm really bad with names. So when I say them, I'm just praying internally, I'm getting them right, even though I've known Martine and James for so long.

But thank you so much, Martine and James for joining us. We've got Dewey, I believe, who's got a quick -- something to read. And then Martine will give us a an update on United Therapeutics, and we'll go into the fireside chat.

Dewey Steadman;Hartaj Singh
United Therapeutics Corporation - Head of IR;Oppenheimer & Co. Inc., Research

Yes. Good afternoon. Our remarks today may include forward-looking information about our business, and please see our SEC filings for risks and uncertainties that could cause actual results to differ. And thanks, Hartaj.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot